The BIO International Convention 2026, the world’s premier biotechnology conference, gathered over 20,000 attendees from diverse sectors including pharmaceuticals, biotechnology, academia, and government organizations. This annual event serves as a crucial platform for discussing the latest trends, technologies, and business strategies in the life sciences industry.
This year’s conference highlighted four significant trends: the integration of AI in R&D China’s expanding influence, the impact of patent cliffs and the rise of emerging biotech companies. These themes are reshaping the industry and hold profound implications for the future of healthcare.
The Transformative Impact of AI on Drug Development
The role of artificial intelligence in drug development was a dominant theme at BIO 2026. The conference featured the second-annual AI summit and numerous sessions dedicated to AI’s potential in R&D. Experts from Eli Lilly, Charles River, Insitro, Chai Discovery, and Benchling discussed how AI can revolutionize drug development by enabling the creation of previously unimaginable medicines.
One notable example is Eli Lilly’s TuneLab a platform that offers AI/ML models in exchange for training data. Insitro has made significant strides in AI-driven analysis of large-scale genetic datasets, identifying potential genetic drivers of diseases like ALS. The industry is increasingly focused on leveraging AI to enhance productivity, decision-making, and R&D success.
Investor enthusiasm for AI-enabled companies is evident, with high-value funding rounds such as Xaira Therapeutics’ $1 billion Series A round in 2026 and Converge Bio’s recent $25 million round. The discussions at BIO 2026 underscored the industry’s shift from debating AI’s role to identifying specific areas where it can deliver measurable improvements.
China’s Growing Influence in the Biotech Industry
China’s role in the biotech industry has evolved significantly, as highlighted at BIO 2026. The country’s sustained government investment, favorable policies, and regulatory reforms have accelerated drug development and streamlined clinical pathways. China has embraced AI and robotics more rapidly than Western markets, leading to dramatic growth and innovation.
Weichang Zhou, CTO of Medilink Therapeutics, noted that the time to advance from an idea to clinical testing in China has reduced from three years to less than a year. This rapid progress is attributed to shorter clinical trial enrolment times and pragmatic solutions to industry challenges. The FDA’s Operation Trailblazer initiative aims to encourage more early clinical trials in the US, addressing concerns about geopolitical uncertainty and investment restrictions.
Despite geopolitical challenges, there was a strong sentiment at BIO 2026 that restricting cross-border collaboration risks slowing innovation and limiting patient access to new therapies. With approximately one-third of licensing deals in 2026 involving China, the industry recognizes the importance of global collaboration.
Navigating the Challenges of Patent Cliffs
The impending expiration of blockbuster drug patents is a significant challenge for the pharmaceutical industry. Drugs like Sanofi’s Dupixent and Merck’s Keytruda are losing patent protection, prompting companies to seek external innovation through licensing, collaborations, and acquisitions. M&A activity has surged in 2026, with over $135 billion exchanged across more than 200 deals.
Pharmaceutical companies are balancing inorganic growth through M&A and joint ventures with organic growth through internal innovation. Allison Kean, Global BD Search & Evaluation Team Leader at Pfizer, emphasized the importance of prioritizing therapeutic areas with long-term growth potential. Immunology, oncology, cardiometabolic, and neurology are cited as key areas capable of generating future blockbuster revenues.
Emerging biotechs play a crucial role in this strategy, providing access to innovative assets. The industry is increasingly selective in capital allocation, focusing on large addressable markets and differentiated therapeutic programs.
The Rise of Emerging Biotech Companies
Emerging biotech companies are at the forefront of innovation in drug development. These companies are responsible for 72% of the clinical pipeline intended for the US market, up from 55% the previous year. They are particularly active in areas like immunology, psychiatry, and ophthalmology, pursuing novel mechanisms rather than incremental improvements.
BIO’s Startup Stadium showcased 50 startups from seven different countries, highlighting highly differentiated science across various therapeutic areas. Companies like Mangrove Therapeutics and ENU Medicines are developing first-in-class therapies targeting unmet patient needs. There is also a growing focus on rare diseases that have historically received limited attention.
However, early-stage companies face challenges in raising pre-seed, seed, and Series A financing. Investors are increasingly risk-averse, preferring to fund later-stage, de-risked assets. Grant funding and partnerships are key steps in bridging the gap to traditional venture capital.
BIO 2026 highlighted an industry balancing short-term commercial pressures with the need for long-term innovation. Despite challenges, there is a strong sentiment that 2026 and beyond could mark the beginning of a new era of growth driven by technological advances, strategic dealmaking, and the rise of emerging biotech companies. The industry’s resilience and commitment to advancing novel therapies were evident throughout the conference.
